A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer.
Adding the drug enzalutamide to standard hormone therapy reduced the risk of premature death by more than 40% in patients whose prostate cancer had returned, a large international clinical trial has found.
The findings were simultaneously published in The New England Journal of Medicine and presented Sunday at a meeting of the European Society for Medical Oncology in Berlin.
The trial focused on patients with what's called high-risk biochemically recurrent prostate cancer. These are men who have already undergone surgery or radiation therapy, but whose blood tests show a rapid, concerning rise in prostate-specific antigen levels.
Related
